Science Names Cancer Immunotherapy its 2013 Breakthrough of the Year
MD Anderson News Release 12/19/13
New reality for long-time dream of medical researchers is grounded in work by Jim Allison
Detect. Destroy. Remember. The mantra of the immune system’s relentless campaign against infectious invaders and the body’s own abnormal cells finally is applying to cancer in meaningful ways.
The journal Science today named cancer immunotherapy its 2013 Breakthrough of the Year, the...
Affiliation between Orlando Health and The University of Texas MD Anderson Cancer Center set to expire
MD Anderson News Release 12/16/13
After working together for more than 23 years to accomplish their joint goal of raising the quality...
MD Anderson researcher Jim Allison wins Breakthrough Prize for his innovative cancer immunology research
Discoveries in T cell biology, development of immune checkpoint blockade cancer therapy honored
MD Anderson News Release...
Younger, early breast cancer patients often undergo unnecessary staging, imaging procedures at time of diagnosis
MD Anderson News Release 12/12/13
Abstract #P3-06-02
Listen to Podcast
More than one third of younger, early stage breast cancer patients undergo unnecessary imaging procedures – including position emission tomography (PET), computed tomography (CT), nuclear medicine bone scans (NMBS) and tumor markers (TM) -- at the time of staging and diagnosis, according to research from The University of Texas MD Anderson Cancer...
Targeted antibody, immune checkpoint blocker rein in follicular lymphoma
Combination therapy sparks complete responses in 52 percent of patients in clinical trial
MD Anderson News Release 12/...
MD Anderson physician receives Susan G. Komen’s highest honor for excellence in breast cancer research
Gordon Mills, M.D., Ph.D., professor and chair of Systems Biology at The University of Texas MD Anderson Cancer Center, will...
Ibrutinib and rituximab trigger 95 percent response rate among CLL patients
Proportion of patients reporting good quality of life goes from 46 to 89 percent in six months
MD Anderson News Release...
Ibrutinib suppression of chronic lymphocytic leukemia endures in second year
Disease progression halted in 76 percent of patients at 30 months, side effects decline
MD Anderson News Release 12/09/...
Clinical trials use Sleeping Beauty gene transfer to create CAR T cells
First-in-human application of T cells modified by “awakened” DNA sequence system reveals no toxicities from treatment after...
Cancer-promoting protein is vital to safe division of tumor cells
PKM2 controls mitosis, saving cancer cells from death and promoting brain tumor growth
MD Anderson News Release...